1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane | 119189-25-2

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 二苄基丁烷木脂素
• 英文名称: 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane
• 英文别名: meso-1,4-bis-(3,4-diethoxy-phenyl)-2,3-dimethyl-butane；2.3-Dimethyl-1.4-bis-(3.4-diaethoxy-phenyl)-butan；meso-1,4-Bis-(3,4-diaethoxy-phenyl)-2,3-dimethyl-butan；1,1'-(2,3-Dimethylbutane-1,4-diyl)bis(3,4-diethoxybenzene)；4-[4-(3,4-diethoxyphenyl)-2,3-dimethylbutyl]-1,2-diethoxybenzene
• CAS: 119189-25-2
• 化学式: C₂₆H₃₈O₄
• 分子量: 414.585
• InChiKey: LLALADYYCUXSAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  硫酸二乙酯 、 alkaline earth salt of/the/ methylsulfuric acid 在 alkaline solution 作用下， 生成 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane
  参考文献：
  名称：

  Waller; Gisvold, Journal of the American Pharmaceutical Association (1912), 1945, vol. 34, p. 78,79

  摘要：

  DOI：

文献信息

• Pharmaceutical compositions comprising catecholic butanes
  申请人：BLOCK DRUG COMPANY, INC.

  公开号：EP0297733A2

  公开（公告）日：1989-01-04

  The invention relates to pharmaceutical compositions useful in the treatment of benign, premalignant and malignant solid tumours, especially those of the skin, and in the treatment of other disorders of the skin e.g. psoriasis and acne. The compositions comprise at least one catecholic butane. The preferred catecholic butane is nordihydroguaiaretic acid. The compositions are preferably applied topically or by intratumor or subcutaneous injection. The invention also includes sunscreening agents comprising at least one catecholic butane.

  本发明涉及可用于治疗良性、恶性前和恶性实体瘤（尤其是皮肤肿瘤）以及其他皮肤疾病（如牛皮癣和痤疮）的药物组合物。组合物包含至少一种儿茶酚丁烷。首选的儿茶酚丁烷是去氢愈创木酚酸。组合物最好局部使用或通过瘤内注射或皮下注射。本发明还包括包含至少一种儿茶酚丁烷的防晒剂。
• COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC
  申请人：CHEMEX PHARMACEUTICALS, INC.

  公开号：EP0288534A1

  公开（公告）日：1988-11-02
• EP0288534A4
  申请人：——

  公开号：EP0288534A4

  公开（公告）日：1989-02-23
• USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY
  申请人：Triact Therapeutics, Inc.

  公开号：EP2349235A1

  公开（公告）日：2011-08-03
• Cancer Therapy
  申请人：White Thomas F.

  公开号：US20100256232A1

  公开（公告）日：2010-10-07

  The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.